Vadimezan Uses, Dosage, Side Effects and more
| Trade Name | Vadimezan |
| Generic | Vadimezan |
| Vadimezan Other Names | 5,6-MeXAA, Dimethyloxoxanthene acetic acid, DMXAA, Vadimezan, Vadimézan, Vadimezanum |
| Type | |
| Formula | C17H14O4 |
| Weight | Average: 282.2907 Monoisotopic: 282.089208936 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.
How Vadimezan works
ASA404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The proposed mechanism of action for ASA404 is directly increasing permeability of the tumor's endothelial cells. Vasoactive mediators such as tumor necrosis factor (TNF) may also be implicated. Increased permeability of tumor cell vasculature may allow increased permeation of anticancer treatments such as cytotoxic drugs, antibodies, drug conjugates and gene therapy.
